

12 March 2026

Osteopore secures distribution rights for injectable regenerative bone filler

Highlights

- Osteopore secures non-exclusive distribution rights from the Biomedical division of dsm-firmenich, a global leader in nutrition, health, and beauty, for its injectable regenerative bone filler for Southeast Asia (SEA). dsm-firmenich is also listed on Euronext Amsterdam (AMS: DSFIR), with a market capitalisation of approximately EUR 15 billion.
- The injectable regenerative bone filler is a complementary addition to Osteopore's growing product portfolio in orthopaedics.
- This signal increases market appreciation for Osteopore's commercialisation ability by other medical device companies and thereby provides a new revenue stream of products distribution.
- The SEA region's share of the Asia Pacific (APAC) orthobiologics and bone graft substitutes market is estimated to be ~AUD 94.6 to AUD 284m (~10-30% of the APAC market size) and is expanding with increased healthcare spending, trauma incidence and surgical capacity across countries such as Singapore, Thailand, Malaysia, and Indonesia.

Australian-Singaporean regenerative medicine company **Osteopore Limited (ASX: OSX; Osteopore or Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to secure the distribution rights from the Biomedical division of dsm-firmenich for its injectable regenerative bone filler in Southeast Asia (SEA). dsm-firmenich is listed on Euronext Amsterdam (AMS: DSFIR) with a market capitalisation of approximately EUR 15 billion.



The injectable regenerative bone filler is a complementary addition to Osteopore's growing product portfolio in orthopaedics, supplementing its recently launched product line. This new product line allows the treatment of various orthopaedic bone defects via a minimally invasive approach. The injectable nature also allows it to fill irregular sized bone gaps, which are very common in trauma and reconstruction surgery.

This latest agreement signals the increasing market endorsement of Osteopore's commercialisation strategy and execution by other medical device companies. Distribution of complementary products creates a new revenue stream for Osteopore.

The Southeast Asia (SEA) region consists of the following 11 countries: Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar (Burma), Philippines, Singapore, Thailand, Timor-Leste (East Timor), and Vietnam.

The SEA segment of the injectable bone graft/orthobiologics market represents a fast-growing component of the broader Asia Pacific (APAC) bone grafts and substitutes market, which was estimated at USD 662.4m (~AUD 946m) in 2024 and is forecast to expand at a compound annual growth rate (CAGR) of ~8.2 % from 2025–2030 driven by rising orthopaedic procedure volumes, an ageing population, and greater adoption of minimally invasive technologies ¹.

The SEA region's share of the APAC orthobiologics and bone graft substitutes market is estimated to be ~10-30% (~AUD 94.6 to AUD 284m) and is expanding with increased healthcare spending, trauma incidence and surgical capacity across countries such as Singapore, Thailand, Malaysia, and Indonesia.

¹ <https://www.grandviewresearch.com/industry-analysis/asia-pacific-bone-grafts-substitutes-market>



Key terms of the agreement:

- Nominal fee payable by Osteopore to DSM for support in product registration
- Non-exclusive distribution rights for Southeast Asia for 3 years from 2026 to 2028
- Minimum Order Quantity applicable on a yearly basis

Following the signing of the distribution agreement, Osteopore shall commence product registration starting from Singapore, followed by progressive expansion to other SEA countries in line with Osteopore's commercial intent and objectives in the SEA region.

Commenting on the addition of a new product line, CEO Dr Yujing Lim, said:

"Osteopore's broader product strategy is in regenerative medicine. This product line aligns well with our commercial strategy, and we are keen to embark on the next steps and accelerate its introduction to the market.

"This product strengthens our product offering, and allows us to further optimise our existing sales channels in Singapore and Southeast Asia", said Dr Lim.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Mark Leong

Executive Chairman

Osteopore Limited

E: mark_leong@osteopore.com



About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

